Payment overview · 2025
General Payments
$69.13
4 reported records · 3 companies
Healthcare provider profile · identity verified
Michael Stens, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · FORT MYERS, FL · NPI 1326097114
Verified facts
What the public records show
CMS Open Payments records show Michael Stens, D.O. received $69.13 in general payments during 2025 across 4 reported records.
PFIZER INC. accounted for 45.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.41 | 45.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.00 | 28.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.72 | 25.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $69.13 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
154 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1118 | 246 |
| Atorvastatin Calcium | Atorvastatin Calcium | 978 | 279 |
| Amlodipine Besylate | Amlodipine Besylate | 753 | 224 |
| Lisinopril | Lisinopril | 554 | 149 |
| Simvastatin | Simvastatin | 480 | 129 |
| Losartan Potassium | Losartan Potassium | 455 | 126 |
| Metoprolol Succinate | Metoprolol Succinate | 420 | 122 |
| Alprazolam | Alprazolam | 374 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 368 | 114 |
| Omeprazole | Omeprazole | 349 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 321 | 99 |
| Gabapentin | Gabapentin | 315 | 89 |
| Metformin Hcl | Metformin Hcl | 298 | 85 |
| Potassium Chloride | Potassium Chloride | 285 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 269 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 256 | 71 |
| Furosemide | Furosemide | 243 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 241 | 70 |
| Trazodone Hcl | Trazodone Hcl | 226 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 213 | 67 |
| Tramadol Hcl | Tramadol Hcl | 191 | 58 |
| Meloxicam | Meloxicam | 183 | 57 |
| Atenolol | Atenolol | 175 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 172 | 49 |
| Prednisone | Prednisone | 170 | 107 |
| Allopurinol | Allopurinol | 159 | 51 |
| Eliquis | Apixaban | 154 | 38 |
| Montelukast Sodium | Montelukast Sodium | 143 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 53 |
| Ozempic | Semaglutide | 135 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 42 |
| Carvedilol | Carvedilol | 132 | 35 |
| Donepezil Hcl | Donepezil Hcl | 130 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 130 | 35 |
| Ezetimibe | Ezetimibe | 129 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 51 |
| Sertraline Hcl | Sertraline Hcl | 123 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 120 | 33 |
| Lorazepam | Lorazepam | 120 | 23 |
| Synthroid | Levothyroxine Sodium | 119 | 27 |
| Azithromycin | Azithromycin | 118 | 99 |
| Glipizide Er | Glipizide | 115 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 104 | 21 |
| Metformin Hcl Er | Metformin Hcl | 103 | 30 |
| Clonazepam | Clonazepam | 101 | 21 |
| Spironolactone | Spironolactone | 97 | 31 |
| Famotidine | Famotidine | 96 | 28 |
| Torsemide | Torsemide | 93 | 31 |
| Memantine Hcl | Memantine Hcl | 88 | 17 |
| Finasteride | Finasteride | 85 | 24 |
| Glipizide | Glipizide | 84 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 23 |
| Januvia | Sitagliptin Phosphate | 82 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 73 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 71 | 61 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 63 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 19 |
| Celecoxib | Celecoxib | 62 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 21 |
| Alendronate Sodium | Alendronate Sodium | 61 | 17 |
| Jardiance | Empagliflozin | 61 | 17 |
| Propranolol Hcl | Propranolol Hcl | 60 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 15 |
| Diazepam | Diazepam | 57 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 39 |
| Ondansetron Odt | Ondansetron | 55 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 38 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 53 | 11 |
| Clonidine Hcl | Clonidine Hcl | 52 | 13 |
| Glimepiride | Glimepiride | 52 | 17 |
| Valsartan | Valsartan | 52 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 14 |
| Warfarin Sodium | Warfarin Sodium | 52 | 14 |
| Pregabalin | Pregabalin | 51 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 15 |
| Baclofen | Baclofen | 46 | 11 |
| Ketoconazole | Ketoconazole | 46 | 28 |
| Mirtazapine | Mirtazapine | 46 | 16 |
| Farxiga | Dapagliflozin Propanediol | 45 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 45 | suppressed |
| Estradiol | Estradiol | 44 | 11 |
| Temazepam | Temazepam | 43 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | 11 |
| Xarelto | Rivaroxaban | 41 | 13 |
| Meclizine Hcl | Meclizine Hcl | 39 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 25 |
| Benazepril Hcl | Benazepril Hcl | 37 | 12 |
| Hydrocortisone | Hydrocortisone | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 11 |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 21 |
| Irbesartan | Irbesartan | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 16 |
| Creon | Lipase/Protease/Amylase | 27 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 11 |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 12 |
| Linzess | Linaclotide | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 12 |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | 11 |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 17 |
| Nystatin | Nystatin | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $69.13 · 4 records | PFIZER INC. | JARDIANCE, OTEZLA, REPATHA, VYNDAQEL | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error